SANTA CRUZ BIOTECHNOLOGY, INC.

EGFL8 (E-12): sc-132284



The Power to Question

BACKGROUND

The epidermal growth factor (EGF) repeat-containing proteins constitute an expanding family of proteins that are involved in several cellular activities, such as blood coagulation, fibrinolysis, cell adhesion and neural and vertebrate development. EGFL8 (EGF-like domain-containing protein 8), also known as C6orf8, NG3 and VE-statin-2, is a 293 amino acid secreted protein that contains two EGF-like domains and one EMI domain. Via its EGF and EMI domains, EGFL8 may participate in protein-protein interactions that correlate with cellular proliferation and developmental signaling events. In mice, EGFL8 is expressed predominately in brain, kidney, lung and thymus.

REFERENCES

- Appella, E., Weber, I.T. and Blasi, F. 1988. Structure and function of epidermal growth factor-like regions in proteins. FEBS Lett. 231: 1-4.
- Davis, C.G. 1990. The many faces of epidermal growth factor repeats. New Biol. 2: 410-419.
- 3. Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 609897. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/
- Callebaut, I., Mignotte, V., Souchet, M. and Mornon, J.P. 2003. EMI domains are widespread and reveal the probable orthologs of the *Caenorhabditis elegans* CED-1 protein. Biochem. Biophys. Res. Commun. 300: 619-623.
- Xie, T., Rowen, L., Aguado, B., Ahearn, M.E., Madan, A., Qin, S., Campbell, R.D. and Hood, L. 2003. Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse. Genome Res. 13: 2621-2636.
- Fitch, M.J., Campagnolo, L., Kuhnert, F. and Stuhlmann, H. 2004. EGFL7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev. Dyn. 230: 316-324.
- 7. Zhang, Z. and Henzel, W.J. 2004. Signal peptide prediction based on analysis of experimentally verified cleavage sites. Protein Sci. 13: 2819-2824.

CHROMOSOMAL LOCATION

Genetic locus: Egfl8 (mouse) mapping to 17 B1.

SOURCE

EGFL8 (E-12) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the N-terminus of EGFL8 of mouse origin.

PRODUCT

Each vial contains 200 μg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-132284 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

EGFL8 (E-12) is recommended for detection of EGFL8 isoforms 1 and 2 of mouse and rat origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with other EGFL family members.

Suitable for use as control antibody for EGFL8 siRNA (m): sc-144600, EGFL8 shRNA Plasmid (m): sc-144600-SH and EGFL8 shRNA (m) Lentiviral Particles: sc-144600-V.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluo-rescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.